June 2025
1. DING M, Wu G, Zhang S, Xie R, et al
   Clinical implications and application of molecular testing in the diagnosis and management of thyroid nodules in the Chinese population.
   Clin Cancer Res. 2025 Jun 27. doi: 10.1158/1078-0432.CCR-25-0270.
   

   >> Share

   
   
2. HARRISON C, Blake AK, Su Y, Tang L, et al
   Contribution of Germline Predisposition to Pediatric Thyroid Cancer.
   Clin Cancer Res. 2025 Jun 27. doi: 10.1158/1078-0432.CCR-25-0631.
   

   >> Share

   
   March 2025
3. LEE J, Shin Y, Kwak J, Park HL, et al
   Validation of Diagnostic Utility of Washout CYFRA 21-1 in Lymph Node Metastasis of Thyroid Cancer.
   Clin Cancer Res. 2025 Mar 12. doi: 10.1158/1078-0432.CCR-24-3562.
   

   >> Share

   
   November 2024
4. LI Q, Zhang W, Liao T, Gao Y, et al
   An AI-driven preoperative radiomic subtype for predicting the prognosis and treatment response of patients with papillary thyroid carcinoma.
   Clin Cancer Res. 2024 Nov 13. doi: 10.1158/1078-0432.CCR-24-2356.
   

   >> Share

   
   June 2024
5. FRENCH JD, Haugen BR, Worden FP, Bowles DW, et al
   Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.
   Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-23-3417.
   

   >> Share

   
   May 2024
6. HEFT NEAL ME, Haring CT, Bellile E, Jaffe CC, et al
   Phase II Clinical Trial of Intravenous Levothyroxine to Mitigate Pharyngocutaneous Fistula in Euthyroid Patients Undergoing Salvage Laryngectomy.
   Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-24-0782.
   

   >> Share

   
   
7. PENG X, Zhao H, Ye L, Hou F, et al
   Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics.
   Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806.
   

   >> Share

   
   April 2024
8. READ ML, Brookes K, Zha L, Manivannan S, et al
   Combined Vorinostat and Chloroquine Inhibit Sodium-Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo.
   Clin Cancer Res. 2024;30:1352-1366.
   

   >> Share

   
   January 2024
9. LECHNER MG, Brent GA
   A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer.
   Clin Cancer Res. 2024 Jan 10. doi: 10.1158/1078-0432.CCR-23-3503.
   

   >> Share

   
   December 2023
10. KIM YH, Yoon SJ, Kim M, Kim HH, et al
    Integrative multi-omics analysis reveals different metabolic phenotypes based on molecular characteristics in thyroid cancer.
    Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-2025.
    

    >> Share

    
    November 2023
11. SHEN C, Shi X, Wen D, Zhang Y, et al
    Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System.
    Clin Cancer Res. 2023 Nov 6. doi: 10.1158/1078-0432.CCR-23-2142.
    

    >> Share

    
    October 2023
12. FU H, Huang J, Zhao T, Wang H, et al
    Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.
    Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1983.
    

    >> Share

    
    September 2023
13. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2023;29:3573-3578.
    

    >> Share

    
    August 2023
14. CHI Y, Zheng X, Zhang Y, Shi F, et al
    Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase â…¡ Trial.
    Clin Cancer Res. 2023 Aug 18:CCR-22-3406. doi: 10.1158/1078-0432.CCR-22-3406.
    

    >> Share

    
    June 2023
15. HU H, Ng TSC, Kang M, Scott E, et al
    Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response.
    Clin Cancer Res. 2023 Jun 8:CCR-22-2976. doi: 10.1158/1078-0432.CCR-22-2976.
    

    >> Share

    
    
16. BIKAS A, Ahmadi S, Pappa T, Marqusee E, et al
    Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
    Clin Cancer Res. 2023 Jun 1:OF1-OF8. doi: 10.1158/1078-0432.CCR-23-0278.
    

    >> Share

    
    May 2023
17. BIKAS A, Ahmadi S, Pappa T, Marqusee E, et al
    Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
    Clin Cancer Res. 2023 May 16:CCR-23-0278. doi: 10.1158/1078-0432.CCR-23-0278.
    

    >> Share

    
    
18. LIN Y, Qin S, Yang H, Shi F, et al
    Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer.
    Clin Cancer Res. 2023 May 15:CCR-22-3613. doi: 10.1158/1078-0432.CCR-22-3613.
    

    >> Share

    
    April 2023
19. LEBOULLEUX S, Do Cao C, Zerdoud S, Attard M, et al
    A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer.
    Clin Cancer Res. 2023 Apr 19:CCR-23-0046. doi: 10.1158/1078-0432.CCR-23-0046.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share